ArticleMolecular cell2009
Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex.
Article in Molecular cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 citations in OpenAlex.
- An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo.Protein science : a publication of the Protein Society · 2025Article
- Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.Frontiers in neurology · 2025Review
- Engineered chimeric receptors for dissecting interferon signaling.Journal of virology · 2024Review
- Membrane-proximal motifs encode differences in signaling strength between type I and III interferon receptors.Science signaling · 2023Article
- Synthetic Heterodimers of Type III Interferon Receptors Require TYK2 for STAT Activation.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023Article
- Whether Erythropoietin can be a Neuroprotective Agent against Premature Brain Injury: Cellular Mechanisms and Clinical Efficacy.Current neuropharmacology · 2022Review
- IFN-γ directly inhibits the activity of erythropoietin in human erythroid progenitors.Blood cells, molecules & diseases · 2020Article
- Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor.Drug design, development and therapy · 2020Article
- Kidney-secreted erythropoietin lowers lipidemia via activating JAK2-STAT5 signaling in adipose tissue.EBioMedicine · 2019Article
- Alternative Erythropoietin Receptors in the Nervous System.Journal of clinical medicine · 2018Review
- Computational analysis of ligand-receptor interactions in wild-type and mutant erythropoietin complexes.Advances and applications in bioinformatics and chemistry : AABC · 2018Article
- Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.Expert opinion on therapeutic targets · 2016Review
- Immunosuppressive effects of erythropoietin on human alloreactive T cells.Journal of the American Society of Nephrology : JASN · 2014Article
- Effect of erythropoietin on primed leucocyte expression profile.Open biology · 2014Article
- Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration.The Journal of experimental medicine · 2013Review
- Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- The pleiotropic effects of erythropoietin in infection and inflammation.Microbes and infection · 2012Review
- Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production.Nature communications · 2011Article
- The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2011Review
- Sortase-catalyzed transformations that improve the properties of cytokines.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Via sites 1 and 2, erythropoietin binds asymmetrically to two identical receptor monomers, although it is unclear how asymmetry affects receptor activation and signaling. Here we report the design and validation of two mutant erythropoietin receptors that probe the role of individual members of the receptor dimer by selectively binding either site 1 or site 2 on erythropoietin. Ba/F3 cells expressing either mutant receptor do not respond to erythropoietin, but cells co-expressing both receptors respond to erythropoietin by proliferation and activation of the JAK2-Stat5 pathway. A truncated receptor with only one cytosolic tyrosine (Y343) is sufficient for signaling in response to erythropoietin, regardless of the monomer on which it is located. Similarly, only one receptor in the dimer needs a juxtamembrane hydrophobic L253 or W258 residue, essential for JAK2 activation. We conclude that despite asymmetry in the ligand-receptor interaction, both sides are competent for signaling, and appear to signal equally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.